Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT02321878

U1111-1157-6701 (Other Identifier)

NN2211-4175

Details and patient eligibility

About

This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.

Enrollment: 1,092 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)
• Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral anti-diabetes drug) other than SU (sulfonylurea)
• Male or female, no age limitation

Exclusion criteria

• Previous participation in this study or NN2211-3772 Participation is defined as informed consent obtained for this study or enrolment for NN2211-3772
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
• Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment

Trial design

1,092 participants in 1 patient group

Liraglutide

Treatment:

Drug: liraglutide